FSIPP has been a leader in promoting fair legislation, access to care and protecting reimbursement. We continue to educate payors, state officials and organizations regarding our area of expertise. We must take ownership of our speciality, promote well developed research and continue to expand our mission in the public and political arena.
To promote the development and practice of safe, high quality, cost-effective interventional pain management techniques for the diagnosis and treatment of pain and related disorders, and to ensure patient access to interventional pain medicine (or management) doctors and these treatments in the State of Florida.
Dr. Orlando G. Florete, Jr., would like to invite you to this year’s CME program that is scheduled for August 20, 2016. We will be at a new location this year, DoubleTree by Hilton Jacksonville Riverfront.
This program is open to all physicians, nurses and PA-C’s interested in attending. Please feel free to share the invitation with your colleagues.
Courses now available for download. Click Here
August 29, 2016
Dear FSIPP Members,
The purpose of this information is to help your hospital administrators and leading clinicians submit comments to CMS about its proposed reimbursement reduction for vertebral augmentation in CY17. Based upon Medicare's own data, Vertebral Augmentation should be reassigned to a Level 5 procedure. The suggested comment below needs to be submitted to CMS before September 6, 2016 @ 5pm (est). It is very easy to submit an online comment via this link:
August 5, 2016
Congratulations to Dr. Orlando Florete, President of FSIPP, for being elected to the FMA's Specialty Society Section’s Governing Council as a At-Large Member.
Clinical Diagnosis and Management
Andrea M. Trescot, MD
Medical Director - Pain and Headache Center
Featured as a single volume, this is a comprehensive guide to possible nerve entrapment syndromes and their management. Click here for Free Preview and to order.
May 27, 2016
REGARDING: CMS News Update - The Pulse of CMS Spring 2016
Click Here to download the entire edition.
March 23, 2016
FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes
The U.S. Food and Drug Administration (FDA) is warning about several safety issues with the entire class of opioid pain medicines. These safety risks are potentially harmful interactions with numerous other medications, problems with the adrenal glands, and decreased sex hormone levels. We are requiring changes to the labels of all opioid drugs to warn about these risks.
February 25, 2016
REGARDING: MEANINGFUL USE ATTESTATION
MGMA is recommending that all physicians, healthcare facility groups and hospitals apply for the meaningful use hardship exception. The reason being, is that even if you have already attested, we have no idea how CMS will handle these attestations, as they were so late in clarifying the measures. Additionally, some of you are counting on your EHR or registry to successfully submit your data, which may not happen. This will not prevent you from a bonus if your attestation is successful and you are in a bonus category. But if anything goes wrong it will prevent you from a 3% cut on all Medicare claims in 2019. The deadline for submitting the hardship extension is March 15, 2016.
SELECT 2.2d AS THE REASON FOR THE HARDSHIP APPLICATION.
Harold Cordner, MD
The use of opioids to treat acute and chronic nonmalignant and malignant pain has steadily increased since the late 1990s. With this increase in opioid use, prescription opioid abuse increased to epidemic proportions. In 2012, an estimated 2.1 million Americans suffered through substance-abuse problems related to prescription opioid pain relievers. Florida was the epicenter of prescription-drug abuse, overdose deaths and "pill mills."
Since 2010, the state of Florida has drastically reduced the accidental deaths due to prescription opioid abuse through legislation, the enactment of the Prescription Drug Monitoring Program, the crackdown on pill mills and other means.
FSIPP President Harold L Dalton, DO in attendance.
DEERFIELD BEACH, Fla. —Fear of the DEA has been a recurring theme in the WESH 2 News ongoing investigation of Florida's prescription drug problem. Patients with real health issues are being denied the medication.
The DEA said it would answer those accusations at Florida's Board of Pharmacy hearing Monday.
"We don't want people to fear us, ...
Articles on Genetics Testing in Pain Management
Reserved for those who donate to the FSIPP PAC or to FSIPP.
Our parent organization is ASIPP, the American Society of Interventional Pain Physicians. Visit ASIPPs website, for a bountiful resource for pain practitioners, and to review a list of ASIPPs accomplishments which have greatly benefited both pain patients and pain physicians.